Intellia Therapeutics, Inc. (NTLA) Revenue History
Annual and quarterly revenue from 2014 to 2025
Compound Annual Growth Rate (CAGR)
Loading revenue history...
NTLA Revenue Growth
NTLA Revenue Analysis (2014–2025)
As of May 6, 2026, Intellia Therapeutics, Inc. (NTLA) generated trailing twelve-month (TTM) revenue of $0, reflecting significant decline in growth of -446.9% year-over-year. The most recent quarter (Q4 2025) recorded $-44,654,000 in revenue, down 424.0% sequentially.
Looking at the longer-term picture, NTLA's historical revenue data shows various trends over time. The company achieved its highest annual revenue of $58.0 million in 2020.
When compared to Healthcare sector peers including CRSP (-81.7% YoY), BEAM (+120.0% YoY), and SGMO (-37.1% YoY), NTLA has underperformed the peer group in terms of revenue growth. Compare NTLA vs CRSP →
NTLA Revenue vs Peers
Revenue metrics vs comparable public companies
| Company | TTM Revenue | YoY Growth | 5Y CAGR | Op. Margin | Compare |
|---|---|---|---|---|---|
| NTLACurrent | $0 | -446.9% | - | - | |
 CRSP | $4M | -81.7% | +37.3% | -18933.6% | |
 BEAM | $140M | +120.0% | +466.3% | -274.6% | |
 SGMO | $58M | -37.1% | -10.8% | -179.9% |
NTLA Historical Revenue Data (2014–2025)
| Year | Revenue | YoY % | Gross Profit | Gross Margin | Op. Income | Op. Margin |
|---|---|---|---|---|---|---|
| 2025 | $0 | -100.0% | $0 | - | $0 | - |
| 2024 | $57.9M | +59.6% | $47.6M | 82.2% | $-534,263,000 | -923.1% |
| 2023 | $36.3M | -30.4% | $27.3M | 75.3% | $-515,291,000 | -1420.5% |
| 2022 | $52.1M | +57.7% | $44.5M | 85.5% | $-458,164,000 | -879.0% |
| 2021 | $33.1M | -43.0% | $26.2M | 79.2% | $-267,850,000 | -810.4% |
| 2020 | $58.0M | +34.5% | $-92,414,000 | -159.4% | $-136,583,000 | -235.5% |
| 2019 | $43.1M | +41.6% | $-65,310,000 | -151.5% | $-106,368,000 | -246.8% |
| 2018 | $30.4M | +16.5% | $-58,681,000 | -192.8% | $-90,870,000 | -298.6% |
| 2017 | $26.1M | +58.5% | $-41,530,000 | -159.0% | $-69,555,000 | -266.3% |
| 2016 | $16.5M | +172.7% | $-15,361,000 | -93.2% | $-32,159,000 | -195.2% |
See NTLA's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs NTLA Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare NTLA vs DBVT
Side-by-side business, growth, and profitability comparison vs DBV Technologies S.A..
Start ComparisonNTLA — Frequently Asked Questions
Quick answers to the most common questions about buying NTLA stock.
Is NTLA's revenue growth accelerating or slowing?
NTLA revenue declined -446.9% year-over-year, contrasting with the 5-year CAGR of N/A. TTM revenue fell to $0.00. This reverses the prior growth trend.
What is NTLA's long-term revenue growth rate?
Intellia Therapeutics, Inc.'s 5-year revenue CAGR of N/A reflects the variable expansion pattern. Current YoY growth of -446.9% is below this long-term average.
How is NTLA's revenue distributed by segment?
NTLA reports revenue by product line and geographic region. Annual and quarterly breakdowns from 2014-2025 are available for download. Segment mix reveals concentration and diversification trends.